Related Experiment Video
Updated: Jun 22, 2026

Evaluation of a Novel Laser-assisted Coronary Anastomotic Connector - the Trinity Clip - in a Porcine Off-pump Bypass Model
Published on: November 24, 2014
Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting
Changqing Gao1, Chonglei Ren, Dong Li
1Department of Cardiovascular Surgery, PLA General Hospital, PLA Institute of Cardiac Surgery, Beijing, China. gaochq301@yahoo.com
Insights
Clopidogrel with aspirin or alone maintains high graft patency after coronary artery bypass grafting (CABG). Both antiplatelet therapies showed similar effectiveness in keeping grafts open long-term.
Area of Science:
- Cardiology
- Vascular Surgery
- Pharmacology
Background:
- Coronary artery bypass grafting (CABG) commonly uses antiplatelet agents like clopidogrel and aspirin.
- Optimal antiplatelet therapy post-CABG and its effect on graft patency remain unclear.
Purpose of the Study:
- To compare the efficacy of clopidogrel alone versus clopidogrel plus aspirin on graft patency after CABG.
- To evaluate long-term graft patency rates in patients receiving different antiplatelet regimens post-CABG.
Main Methods:
- A study involving 197 patients undergoing CABG.
- Patients were randomized to receive either clopidogrel (75 mg daily) or a combination of clopidogrel (75 mg daily) and aspirin (100 mg daily).
- Graft patency was assessed using multislice computed tomography angiography at 1 and 12 months post-CABG.
Main Results:
- No significant differences in pre-operative data between the groups.
- Graft patency rates at 12 months were high in both groups: Left Internal Mammary Artery (LIMA) (96.9% clopidogrel vs. 97.8% combination) and saphenous vein grafts (93.5% clopidogrel vs. 96.3% combination).
- No statistically significant difference in graft patency was observed between the clopidogrel and combination therapy groups (p > 0.05).
Conclusions:
- Both clopidogrel plus aspirin and clopidogrel monotherapy achieve high graft patency rates in the early and late postoperative phases following CABG.
- While a trend towards higher patency with combination therapy was noted, it did not reach statistical significance.
- These findings suggest that either regimen can be considered for maintaining graft patency post-CABG.
Background:
Clopidogrel and aspirin are the most popular antiplatelet agents for anticoagulation management after coronary artery bypass grafting (CABG) in clinical practice, but there is neither a standard antiplatelet therapy for patients undergoing CABG, nor an exact conclusion about its effects on graft patency until now.
Methods:
One-hundred and ninety-seven selected patients undergoing CABG were assigned to two groups according to antiplatelet drug: the clopidogrel group of 102 patients who received clopidogrel (75 mg) daily; and the combination group of 95 patients who received clopidogrel (75 mg) plus aspirin (100 mg) daily. Multislice computed tomography angiography was performed to evaluate graft patency at 1 month and 12 months after CABG.
Results:
There were no significant differences between the two groups in preoperational data. At 1 month and 12 months after CABG graft patency rates of clopidogrel group were, respectively, 99.0% and 96.9% for the left internal mammary artery (LIMA) and 98.1% and 93.5% for the saphenous vein grafts; those of the combination group were, respectively, 98.9% and 97.8% for LIMA, and 98.2% and 96.3% for saphenous vein grafts. There were no significant differences in graft patency between the two groups (p > 0.05).
Conclusions:
Either clopidogrel plus aspirin or clopidogrel alone maintain high graft patency in the early postoperative phase after CABG. The observed trend toward higher patency rates in patients treated with clopidogrel plus aspirin compared to those in the clopidogrel group did not reach statistical significance.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease III: Interprofessional Care
